[go: up one dir, main page]

GT201400153A - Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina - Google Patents

Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina

Info

Publication number
GT201400153A
GT201400153A GT201400153A GT201400153A GT201400153A GT 201400153 A GT201400153 A GT 201400153A GT 201400153 A GT201400153 A GT 201400153A GT 201400153 A GT201400153 A GT 201400153A GT 201400153 A GT201400153 A GT 201400153A
Authority
GT
Guatemala
Prior art keywords
spiroindoline
derivatives
gonadotropine
liberator
antagonists
Prior art date
Application number
GT201400153A
Other languages
English (en)
Inventor
Panknin Olaf
Baurle Stefan
Ring Sven
Schwede Wolfgang
Bone Wilhelm
6 Nowak-Reppel Katrin
Bender Eckhard
Nubbemeyer Reinhard
Gnoth Mark Jean
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47559493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400153(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201400153A publication Critical patent/GT201400153A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

DERIVADOS DE ESPIROINDOLINA, PROCESOS PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS CON LOS MISMOS, SU USO PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES Y SU USO EN LA ELABORACIÓN DE MEDICAMENTOS PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES, EN ESPECIAL ENFERMEDADES RELACIONADAS CON LAS HORMONAS SEXUALES. LA PRESENTE SOLICITUD SE RELACIONA EN PARTICULAR CON DERIVADOS DE ESPIROINDOLINA COMO AGONISTAS DEL RECEPTOR DE LA HORMONA LIBERADORA DE GONADOTROPINA (GNRH).
GT201400153A 2012-01-16 2014-07-16 Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina GT201400153A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12151291 2012-01-16

Publications (1)

Publication Number Publication Date
GT201400153A true GT201400153A (es) 2015-05-22

Family

ID=47559493

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400153A GT201400153A (es) 2012-01-16 2014-07-16 Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina

Country Status (25)

Country Link
US (1) US20140357655A1 (es)
EP (1) EP2804867A1 (es)
JP (1) JP2015503607A (es)
KR (1) KR20140112075A (es)
CN (1) CN104169287A (es)
AP (1) AP2014007738A0 (es)
AU (1) AU2013211091A1 (es)
BR (1) BR112014017483A8 (es)
CA (1) CA2860986A1 (es)
CL (1) CL2014001871A1 (es)
CO (1) CO7010832A2 (es)
CR (1) CR20140343A (es)
CU (1) CU20140088A7 (es)
DO (1) DOP2014000167A (es)
EA (1) EA201491344A1 (es)
GT (1) GT201400153A (es)
HK (1) HK1199878A1 (es)
IL (1) IL233485A0 (es)
MA (1) MA35867B1 (es)
MX (1) MX2014008630A (es)
PE (1) PE20141699A1 (es)
PH (1) PH12014501616A1 (es)
SG (1) SG11201403749VA (es)
TN (1) TN2014000306A1 (es)
WO (1) WO2013107743A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095785A1 (es) * 2013-04-09 2015-11-11 Bayer Pharma AG Derivados de espiroindolina y composiciones farmacéutica de los mismos
WO2015007606A1 (en) * 2013-07-15 2015-01-22 Bayer Pharma Aktiengesellschaft Spiroindoline derivatives and pharmaceutical compositions thereof
WO2015082374A1 (en) * 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Spiroindoline-thiopyran-imine-oxide derivatives as gonadotropin-releasing hormone receptor antagonists and pharmaceutical compositions thereof
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
WO2015091315A1 (en) * 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Spiro[indolin-3,4'-piperidine] derivatives as gnrh receptor antagonists
EP3339846B1 (en) * 2016-12-22 2020-12-09 Malvern Panalytical B.V. Method of measuring properties of a thin film stack
MA49256A (fr) 2017-06-05 2021-05-26 ObsEva SA Schémas posologiques comprenant un antagoniste de l'hormone de libération des gonadotrophines pour le traitement de l'endométriose
CN107840851A (zh) * 2017-12-21 2018-03-27 扬州大学 吲哚螺吡咯嗪化合物及其合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds

Also Published As

Publication number Publication date
HK1199878A1 (en) 2015-07-24
EA201491344A1 (ru) 2015-04-30
SG11201403749VA (en) 2014-07-30
JP2015503607A (ja) 2015-02-02
US20140357655A1 (en) 2014-12-04
CR20140343A (es) 2014-09-08
MX2014008630A (es) 2014-08-29
BR112014017483A8 (pt) 2017-07-04
PE20141699A1 (es) 2014-11-29
DOP2014000167A (es) 2014-08-31
CN104169287A (zh) 2014-11-26
KR20140112075A (ko) 2014-09-22
CO7010832A2 (es) 2014-07-31
IL233485A0 (en) 2014-08-31
PH12014501616A1 (en) 2014-10-13
CL2014001871A1 (es) 2014-11-03
AP2014007738A0 (en) 2014-07-31
EP2804867A1 (en) 2014-11-26
MA35867B1 (fr) 2014-12-01
TN2014000306A1 (en) 2015-12-21
CU20140088A7 (es) 2014-12-26
WO2013107743A1 (en) 2013-07-25
BR112014017483A2 (pt) 2017-06-13
AU2013211091A1 (en) 2014-08-07
CA2860986A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
GT201400153A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
CL2016000922A1 (es) Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4
CL2016001509A1 (es) Formas cristalinas de los análogos de sofosbuvir antivirales
MX2013006304A (es) Analogos de glucagon que exhiben actividad del receptor gip.
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
UY36311A (es) Indazoles sustituidos con bencilo
MX2016012446A (es) Derivados de quinoxalina utiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
CL2015003290A1 (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
CL2016000495A1 (es) Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades.
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX387228B (es) Compuestos de pirazol como moduladores del receptor de hormona estimuladora de foliculo y sus usos.
CL2016001409A1 (es) Inhibidores de quinasa relacionada con la tropomiosina (trk).
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
NI202000029A (es) Amidas de imidazopiridina sustituidas y su uso
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4